Aplastic anemia is one of those diseases that doesn’t get a lot of press, but if you’ve ever met a patient with it, you understand why this matters.
The body’s bone marrow stops making blood cells. Patients become transfusion-dependent. Standard treatment is bone marrow transplant for those who can get one, or immunosuppression for those who can’t. When both fail, options thin out fast.
Cellenkos just got FDA clearance to start Phase 2 of CK0801 in transfusion-dependent aplastic anemia patients who’ve already failed standard care or aren’t eligible for it. The primary endpoint is a 30% or greater reduction in transfusion requirements at six months.
CK0801 is an allogeneic cord blood-derived regulatory T cell (Treg) therapy.
Tregs are one of the immune system’s brakes systems. They suppress overactive immune responses by releasing a BUNCH of immunosuppressive cytokines like IL-10 and TGF-ß.
Well, in aplastic anemia, the patient’s own T cells attack their bone marrow stem cells leaving them with a weakened immune system…their immune system is essentially committing suicide.
Cellenkos’ theory is that infusing donor Tregs can suppress that autoimmune attack and let the marrow recover.
What’s interesting about Cellenkos isn’t this single trial.
It’s that they have five Treg programs running.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
CK0801 is in trials for bone marrow failure, treatment-refractory Guillain-Barré, and ARDS from COVID.
CK0803 is engineered with neurotropic homing markers and is in Phase 1b for ALS.
CK0804 is an NK cell therapy (not a Treg) for myelofibrosis patients with suboptimal ruxolitinib response.
There’s also a Treg combo program that goes after MPNs after Type I JAK inhibitor failure.
This is a platform play built on a manufacturing system they call CRANE.
Cord blood is the source material because cord blood Tregs are functionally distinct from peripheral blood Tregs…basically, they’re more suppressive and easier to expand.
All of their programs are off-the-shelf, allogeneic, no patient-specific manufacturing. Different from Mozart’s antibody approach to activating CD8 Tregs in vivo, but going after the same therapeutic concept from the cell side instead of the small molecule side.
The aplastic anemia trial is the one to watch on commercial potential. Roughly 600 to 900 new cases per year in the US, but the patient pool that fails first-line therapy and isn’t transplant-eligible is meaningful and currently has nothing else. A 30% transfusion reduction would be clinically significant. A higher number could change practice.
What Cellenkos hasn’t done yet is publish efficacy data from any of their Phase 1 work.
The bone marrow failure trial has been recruiting since 2018. The ALS Phase 1 has been active for over two years. So while the platform is broad, the field is still waiting on the data that proves cord blood Tregs do what the company says they do.
Phase 2 in aplastic anemia is the cleanest setup they’ve had. Transfusion requirement is hard to fudge. You’re either getting fewer units of blood or you’re not.
If CK0801 hits, it validates the whole platform.
The Biotech Voyager Podcast
Deep dives on the signals shaping early-stage biotech.
